Free tool
FAERS Monitor: Jublia
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 203567 or its brand name (Jublia, Efinaconazole). Reports on generic versions are filed under their own applications.
Reports
1,962
Serious
727
37% of reports
Hospitalization
404
Death reported
108
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective423
- fatigue244
- pain234
- headache214
- asthenia209
- drug hypersensitivity183
- oedema peripheral180
- anaemia172
- pyrexia170
- product dose omission issue166
- asthma163
- tremor163
- cough162
- lower respiratory tract infection161
- musculoskeletal stiffness161
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2014 | 27 |
| 2015 | 314 |
| 2016 | 329 |
| 2017 | 163 |
| 2018 | 133 |
| 2019 | 99 |
| 2020 | 105 |
| 2021 | 131 |
| 2022 | 119 |
| 2023 | 163 |
| 2024 | 154 |
| 2025 | 133 |
| 2026 | 92 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,197 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| lower respiratory tract infectionSignal | 161 | 38.1 | 32.8 | 5,769 |
| musculoskeletal stiffnessSignal | 161 | 19.7 | 17.0 | 2,851 |
| oedema peripheralSignal | 180 | 15.9 | 13.8 | 2,501 |
| asthmaSignal | 163 | 15.5 | 13.4 | 2,202 |
| tremorSignal | 163 | 10.5 | 9.1 | 1,407 |
| drug hypersensitivitySignal | 183 | 10.1 | 8.8 | 1,512 |
| anaemiaSignal | 172 | 9.7 | 8.4 | 1,340 |
| coughSignal | 162 | 6.2 | 5.3 | 710 |
| product dose omission issueSignal | 166 | 6.1 | 5.2 | 705 |
| astheniaSignal | 209 | 6.0 | 5.2 | 873 |
| pyrexiaSignal | 170 | 5.3 | 4.6 | 593 |
| painSignal | 234 | 4.1 | 3.6 | 558 |
| headacheSignal | 214 | 3.7 | 3.2 | 424 |
| drug ineffectiveSignal | 423 | 3.4 | 3.2 | 779 |
| fatigueSignal | 244 | 3.4 | 3.0 | 418 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.